To prioritize efficacy of combinatorial therapies for BYL719-resistant breast cancer, we exploited our computational models and simulated the effect of various pair-wise drug combinations directed at PI3Kα and other components of the PI3K network. The gene discussed is PIK3CA; the disease is breast cancer.